| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.03. | Futura Medical "very pleased" by Eroxon testing results | 14 | Alliance News | ||
| 23.03. | AIM Market Roundup: Quadrise, Iomart, Futura Medical | 2 | The Armchair Trader | ||
| 23.03. | Futura Medical reports positive trial results for Eroxon products | 1 | Investing.com | ||
| 23.03. | Futura Medical meldet positive Studienergebnisse für Eroxon-Produkte | 1 | Investing.com Deutsch | ||
| 23.03. | Futura Medical PLC - Positive Eroxon & Eroxon "Intense" HUT results | - | RNS | ||
| 18.03. | Futura Medical PLC - Formal Grant of US Patent | 1 | RNS | ||
| FUTURA MEDICAL Aktie jetzt für 0€ handeln | |||||
| 05.02. | Futura Medical PLC - Patent notice of allowance granted for the US | 5 | RNS | ||
| 04.02. | TRADING UPDATES: Futura Medical says 2025 revenue beats own guidance | 2 | Alliance News | ||
| 04.02. | Futura Medical PLC - Trading Update | 2 | RNS | ||
| 12.01. | Futura Medical PLC - Results of WSD4000 Early Feasibility Study | 12 | RNS | ||
| 07.01. | Spreadex reduces stake in Futura Medical to 3.92% | 6 | Investing.com | ||
| 07.01. | Spreadex reduziert Anteil an Futura Medical auf 3,92 % | - | Investing.com Deutsch | ||
| 07.01. | Futura Medical PLC - Notification of major holdings | - | RNS | ||
| 31.12.25 | Futura Medical PLC - Total Voting Rights | 1 | RNS | ||
| 30.12.25 | Cantor Fitzgerald Europe reduziert Beteiligung an Futura Medical | 6 | Investing.com Deutsch | ||
| 30.12.25 | Cantor Fitzgerald Europe reduces stake in Futura Medical | 1 | Investing.com | ||
| 30.12.25 | Futura Medical PLC - Notification of major holdings | 1 | RNS | ||
| 23.12.25 | Lombard Odier reduces stake in Futura Medical to 12.76% | 1 | Investing.com | ||
| 23.12.25 | Futura Medical PLC - Notification of major holdings | 5 | RNS | ||
| 18.12.25 | WT Lamb Investments reduces stake in Futura Medical to 2.25% | 3 | Investing.com |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 30,705 | -0,21 % | JEFFERIES stuft NOVO NORDISK auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Novo Nordisk von 275 auf 270 Kronen gesenkt, aber die Einstufung auf "Hold" belassen. Analyst Michael Leuchten hob am Montagabend... ► Artikel lesen | |
| GILEAD SCIENCES | 118,98 | -0,02 % | Gilead mit Doppelschlag | Zwei milliardenschwere Übernahmen in einem Monat: Die Biotech-Gesellschaft Gilead bleibt äußerst aktiv in Sachen M&A. Nachdem die Amerikaner bereits am 23. Februar die Akquisition des Partners Arcellx... ► Artikel lesen | |
| AURORA CANNABIS | 2,755 | +1,66 % | Panik vor Kursbeben: Das Zittern beginnt: Reißen die Tilray-Zahlen Canopy, Aurora & Co in die Tiefe? | © Foto: adobe.stock.comIn Kürze ist es soweit - Tilray wird frische Quartalszahlen vorlegen. Den Tilray-Zahlen kann man dabei durchaus richtungsweisenden Charakter zubilligen. Entsprechend dürften sie... ► Artikel lesen | |
| CANOPY GROWTH | 0,774 | +3,34 % | Thinking About Buying Canopy Growth Stock? You May Want to Wait for This to Happen First | ||
| TILRAY BRANDS | 5,230 | 0,00 % | Top stocks to watch this week: Tilray Brands, Nike, FactSet | ||
| VERTEX PHARMACEUTICALS | 388,75 | +0,54 % | If You Invested $1000 In Vertex Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today | ||
| INNOCAN PHARMA | 4,020 | -0,99 % | Innocan Pharma Corporation: Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M | Iris Bincovich, CEO of Innocan commented, "We remain firmly focused on executing our strategy and advancing our long-term objectives in the healthcare sector.Our pharmaceutical segment is dedicated... ► Artikel lesen | |
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | TAAT Global Alternatives Inc (2): TAAT Global CEO Saxon resigns | ||
| BIOTEST | 32,000 | 0,00 % | Biotest erhält FDA-Zulassung | Summary: FDA lässt Fibrinogen-Produkt für den US-Markt zu Biotest entwickelt und produziert, Grifols vermarktet Markteinführung für 2026 geplant Pipeline gewinnt strategisch an Gewicht Biotest hat einen... ► Artikel lesen | |
| CRONOS GROUP | 2,088 | -1,79 % | Cronos Group Inc.: Cronos Group Reports 2025 Fourth Quarter and Full-Year Results | Net revenue in Q4 2025 increased by 47% year-over-year to $44.5 million; Net revenue in FY 2025 increased by 25% year-over-year to $146.6 million Achieved record net revenue in Q4 2025 and FY 2025... ► Artikel lesen | |
| SYNBIOTIC | 1,920 | -4,48 % | EQS-News: SYNBIOTIC SE: Globale Dynamik im Cannabismarkt: Neue Signale aus den USA stärken langfristige Perspektiven für Europa und SYNBIOTIC | EQS-News: SYNBIOTIC SE
/ Schlagwort(e): Marktbericht/Sonstiges
Globale Dynamik im Cannabismarkt: Neue Signale aus den USA stärken langfristige Perspektiven für Europa und SYNBIOTIC... ► Artikel lesen | |
| DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc.: Digicann Ventures Announces Agreement to Extend Maturity Date for Convertible Debentures | Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - Digicann Ventures Ltd. (CSE: DCNN.X) ("Digicann" or the "Company"), a company focused on opportunities within and outside of the... ► Artikel lesen | |
| EYEPOINT | 10,635 | +2,90 % | EyePoint Pharmaceuticals: Strategische Fortschritte bei Netzhaut-Therapie DURAVYU auf RBC-Konferenz vorgestellt | ||
| EDWARDS LIFESCIENCES | 69,52 | +0,20 % | What to Expect From Edwards Lifesciences' Next Quarterly Earnings Report | ||
| ORGANIGRAM GLOBAL | 1,060 | -2,75 % | Organigram Global Inc.: Organigram Announces Shareholder Approval of Acquisition of Sanity Group GmbH and Results of its Annual General and Special Meeting | Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), is pleased to announce that the shareholders of Organigram have overwhelmingly approved the resolution required to... ► Artikel lesen |